Facts & Figures
Bayer HealthCare
The Company combines the global activities of the divisions Animal Health, Bayer Schering Pharma and Consumer Care. More than 50,000 people are employed by Bayer HealthCare worldwide
Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.
- Sales 2007: 14,807 Euro million
- Workforce: 51,500 worldwide
- Operating profit 2007: 1,564 Euro million
- Headquarters: Leverkusen, Germany
Divisions of Bayer HealthCare
| Management | Based in |
|---|
Animal Health
| Lykele van der Broek | Monheim, Germany |
| Bayer Schering Pharma | Andreas Fibig | Berlin, Germany |
Consumer Care
| Gary S. Balkema | Morristown, USA |
Diabetes Care
| Sandra E. Peterson | Tarrytown, New York, USA |
Executive Committee
Chairman: Arthur J. Higgins
Members of the Executive Committee
- Gary S. Balkema
- Werner Baumann
- Lykele van der Broek
- Prof. Dr. Andreas Busch
- Andreas Fibig
- Dr. Hartmut Klusik
- Dr. Ulrich Köstlin
- Sandra E. Peterson
- Dr. Kemal Malik
- Dr. Gunnar Riemann
Sales 2007
Sales of the HealthCare subgroup grew by 26.3 percent in 2007, to €14,807 million. The acquired business of Schering AG, Berlin, Germany, is included in this fi gure on a fullyear basis (2006: June 23 – December 31). Adjusted for currency and portfolio effects, sales climbed by 7.3 percent. The increase was due to the positive business performance of both segments.
| 2007 | 2006 | Change
|
|---|
| | € million | € million | % |
| Bayer HealthCare | 14,807 | 11,724 | 26 |
- Division Animal Health
| 956 | 905 | 5.6
|
- Division Consumer Care
| 2,634 | 2,531 | 7.8 |
- Division Diabetes Care
| 950 | 810 | 17.5 |
- Division Bayer Schering Pharma*
| 10,267 | 7,478 | 37.3
|
*The aquired business of Schering AG, Berlin, Germany, is included in this figure on a full-year basis (2006: June 23 -December 31).
Performance 2007
Sales of our Pharmaceuticals segment climbed by 37.3 percent in 2007, to 10,267 million (2006: 7,478 million). This fi gure contains 5,921 million (2006: €3,082 million pro-rated) in sales of the Schering business. Adjusted for portfolio and currency changes, sales were up by 5.7 percent.
In the Consumer Health segment, business expanded by 6.9 percent in 2007, to 4,540 million (2006: 4,246 million). Adjusted for currency and portfolio changes, sales were up by 10.3 percent. We registered above-market growth in all three divisions.
The Consumer Care Division grew sales by 4.1 percent to 2,634 million (2006: 2,531 million). This fi gure takes into account our fi rst sales of the calcium dietary supplement Citracal®, acquired in the fourth quarter from Mission Pharmacal Company of the United States. Currency- and portfolio-adjusted sales improved by 7.8 percent.
The highest growth rates were posted by Berocca® (currency-adjusted: +16.8 percent),
Canesten® (currency-adjusted: +15.4 percent) and Aleve® (currency-adjusted: +13.9 percent).
Sales of the Diabetes Care Division came in at 950 million (2006: 810 million), with
a currency- and portfolio-adjusted increase of 17.5 percent. This gratifying trend was
chiefl y attributable to the successful marketing, particularly in North America and Europe,
of our Ascensia® Contour® and Ascensia® Breeze® blood glucose monitoring systems,
which replace the Elite® systems of the Ascensia® product family.
Sales of the Animal Health Division increased by 5.6 percent to 956 million
(2006: 905 million), or by 10.6 percent when adjusted for currency effects. The performance
of our Advantage® product line was particularly gratifying, with currency-adjusted
sales rising by 20.8 percent. In October 2007, the European Medicines Agency (emea)
expanded the registration for the canine anti-parasitic Advocate®.
Research & Development 2007
In 2007 we invested 1,700 million (2006: 1,426 million) in R&D in the Pharmaceuticals
and Consumer Health segments to lay the foundations for the introduction of further
innovative products in the subgroup’s expanding markets. This represented 65.9 percent
of the Bayer Group’s entire r&d expenditures and was equivalent to 11.5 percent of sales.
